Methods of using conjugated toxin peptide therapeutic agents

US7910102B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• John K. Sullivan · Newbury Park, US
• Joseph G. McGivern · Mountain View, US
• Leslie P. Miranda · Thousand Oaks, US
• Hung Q. Nguyen · Thousand Oaks, US
• Kenneth W. Walker · Newbury Park, US
• Shaw-Fen Sylvia Hu · Thousand Oaks, US
• Colin Gegg · Newbury Park, US
• Taruna Arora Khare · Thousand Oaks, US
• Beverly S. Adler · Newbury Park, US
• Francis H. Martin · Newbury Park, US

Key dates

• Filing date: Oct 25, 2007
• Grant date: Mar 22, 2011
• Expiry date: Sep 3, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.